A number of research firms have changed their ratings and price targets for Illumina (NASDAQ: ILMN):

  • 4/17/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $196.75 price target on the stock.
  • 4/14/2017 – Illumina had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $187.00 price target on the stock, up previously from $170.00.
  • 4/13/2017 – Illumina was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Ahead of its fourth-quarter earnings, we believe, soft margins and tough competition continue to act as major headwinds for Illumina. We are also apprehensive about NIH funding cut related issues which the company is facing for quite some time. As per the new president’s proposed budget plan, we expect this funding issue to aggravate for the company over time. Also Illumina’s slower pace of growth in the U.S. and sluggish sequencing instrument revenues during the fourth quarter 2016 were downsides. On a positive note, we are looking forward to the company’s sequencing portfolio with the latest Novaseq series launch and its tie-up with Bio-Rad. The company also performed well in the Asia Pacific and Europe. In the past three months Illumina is trading neck-to-neck with the broader Medical-Biomed/Genetics industry.”
  • 4/11/2017 – Illumina had its price target raised by analysts at Bank of America Corp from $175.00 to $195.00. They now have a “buy” rating on the stock.
  • 4/11/2017 – Illumina was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $193.40 price target on the stock.
  • 4/6/2017 – Illumina was upgraded by analysts at TheStreet from a “c+” rating to a “b” rating.
  • 4/5/2017 – Illumina had its “buy” rating reaffirmed by analysts at Leerink Swann.
  • 4/4/2017 – Illumina was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $191.00 price target on the stock. According to Zacks, “In the past three months, Illumina's share price, outpaced the broader Medical-Biomed/Genetics industry. The company also performed well in the last reported fourth quarter of 2016. The outperformance was driven by the company’s sequencing portfolio with the latest Novaseq series launch and its tie-up with Bio-Rad. Management’s issuance of 2017 guidance is also encouraging. The company also performed well in the Asia Pacific and Europe. On the flip side, Illumina witnessed a slower pace of growth in the U.S. region. Overall, the year-over-year fall in sequencing instrument revenue due to the challenging HiSeq X comparison marred the entire performance. Soft margins and tough competition continue to be major headwinds.”
  • 4/4/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $190.90 price target on the stock.
  • 3/27/2017 – Illumina was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $188.84 price target on the stock.
  • 3/20/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $187.82 price target on the stock.
  • 3/20/2017 – Illumina was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating. They now have a $195.00 price target on the stock.
  • 3/19/2017 – Illumina had its “hold” rating reaffirmed by analysts at BTIG Research.
  • 3/14/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $184.98 price target on the stock.
  • 2/27/2017 – Illumina was upgraded by analysts at Evercore ISI from a “hold” rating to a “buy” rating. They now have a $190.00 price target on the stock.
  • 2/27/2017 – Illumina was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $183.32 price target on the stock.
  • 2/22/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $181.98 price target on the stock.
  • 2/21/2017 – Illumina had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $150.00 price target on the stock.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at 178.03 on Thursday. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $186.88. The stock has a market cap of $26.05 billion, a PE ratio of 57.99 and a beta of 0.79. The company’s 50-day moving average price is $169.01 and its 200-day moving average price is $152.14.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, January 31st. The life sciences company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.03. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The company had revenue of $619 million for the quarter, compared to analyst estimates of $612.50 million. During the same period in the prior year, the firm posted $0.81 EPS. The business’s revenue was up 4.6% compared to the same quarter last year. Analysts expect that Illumina, Inc. will post $3.64 earnings per share for the current year.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/04/20/analysts-weekly-ratings-updates-for-illumina-ilmn.html

In other Illumina news, Director A Blaine Bowman sold 3,000 shares of the company’s stock in a transaction dated Wednesday, February 8th. The stock was sold at an average price of $162.74, for a total value of $488,220.00. Following the transaction, the director now directly owns 16,204 shares of the company’s stock, valued at approximately $2,637,038.96. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Omead Ostadan sold 259 shares of the company’s stock in a transaction dated Monday, January 30th. The stock was sold at an average price of $160.90, for a total value of $41,673.10. Following the completion of the transaction, the executive vice president now directly owns 27,949 shares in the company, valued at $4,496,994.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,476 shares of company stock worth $2,078,440. Insiders own 1.60% of the company’s stock.

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

5 Day Chart for NASDAQ:ILMN

Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with MarketBeat.com's FREE daily email newsletter.